NCT01876849View on ClinicalTrials.gov

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide

subcutaneous injection, 5mcg or 10 mcg, twice daily

Trial Locations (1)

Unknown

Research Site, Renton

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY